Welcome to our dedicated page for Cellebrite Di SEC filings (Ticker: CLBTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CLBTW SEC filings page on Stock Titan surfaces U.S. regulatory documents connected to Cellebrite DI Ltd., the issuer whose shares trade on Nasdaq as CLBT and to which the CLBTW warrants are linked. As a foreign private issuer based in Israel, Cellebrite files an annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934.
Recent Form 6-K filings referenced in the available data include press releases on second-quarter 2025 financial results and the appointment of a new chief executive officer, as well as the appointment of a chief financial officer and notice of the company’s annual general meeting of shareholders. These 6-Ks often incorporate GAAP financial statement tables and, in some cases, are expressly incorporated by reference into existing registration statements on Form S-8 and Form F-3. For investors tracking CLBTW, such filings help explain Cellebrite’s operating performance, governance changes and capital markets activity.
Cellebrite’s disclosures also discuss the use of non-GAAP financial measures such as non-GAAP gross profit, non-GAAP operating income, non-GAAP net income, Adjusted EBITDA and free cash flow, along with key performance indicators like annual recurring revenue and dollar-based net retention rate. The company explains why it believes these metrics provide additional insight beyond GAAP results, while also outlining their limitations.
On Stock Titan, users can review these SEC submissions in one place and use AI-powered tools to quickly interpret their contents. Filings related to CLBT and the associated warrants can be analyzed to understand how Cellebrite describes its digital investigation and intelligence business, risk factors, equity plans and financing activities. This page is a starting point for examining Form 20-F annual reports, Form 6-K current reports and other registered documents that define the regulatory and financial context for the CLBTW warrants.
Cellebrite DI Ltd. (CLBTW) Form 144 summary: An individual filed a notice to sell 7,867 common shares through Morgan Stanley Smith Barney LLC on 08/19/2025, with an aggregate market value of $127,130.72. The filing reports the shares were acquired as Restricted Stock Units from the issuer on 08/15/2025 and paid on 08/15/2025. The filing also discloses a prior sale by Marcus H Jewell of 15,995 common shares on 08/18/2025 for $249,522.00. The notice states the signer represents no undisclosed material adverse information.
Form 144 filed for CLBTW: proposed sale of 15,995 ordinary shares on Nasdaq. The shares were acquired when 31,728 restricted share units vested under an S-8 plan on 08/15/2025 and were paid as employee compensation. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and shows an aggregate market value of $249,522.00 for the proposed sale.
The filer previously sold 7,384 shares on 05/19/2025 for gross proceeds of $128,555.44. The filing includes the seller's representation that they are not aware of undisclosed material adverse information about the issuer.
Cellebrite DI Ltd. is calling its Annual General Meeting of Shareholders for September 19, 2025, at 4:00 p.m. Israel time at its headquarters in Petah Tikva, Israel. The company is providing a notice and proxy statement, along with a proxy card, so shareholders can review the agenda and vote on the items to be considered at the meeting. The materials furnished with this report are also incorporated by reference into Cellebrite’s existing registration statements on Form S-8 and Form F-3, linking the meeting-related disclosures to its U.S. securities offerings framework.
Cellebrite DI Ltd. furnished a report stating it issued a press release titled “Cellebrite Announces Second-Quarter 2025 Results; Thomas E. Hogan Named CEO.” The company highlights that GAAP financial statement tables from this press release are incorporated by reference into its existing Form S-8 and Form F-3 registration statements.
The Form 6-K furnished on 8 July 2025 by Cellebrite DI Ltd. (symbol: CLBTW) discloses a leadership transition in the finance function. According to the attached press release (Exhibit 99.1), David Barter has been appointed Chief Financial Officer and current CFO Dana Gerner will retire. The filing states that the first paragraph of the press release is incorporated by reference into the company’s existing Form S-8 (File Nos. 333-260878, 333-278130) and Form F-3 (File No. 333-259826) registration statements.
No additional financial metrics, strategic commentary, or effective-date details are included. Apart from the exhibit index and routine signature block, there are no other material disclosures.